Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune has begun dosing of patients in the first Phase I clinical trial of CAM-3001, a fully human monoclonal antibody, to evaluate the safety and tolerability of single doses of the drug in patients with rheumatoid arthritis.
Subscribe to our email newsletter
This trial represents the first clinical trial in which a monoclonal antibody (MAb) targeting granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) is being investigated in this population.
MedImmune currently holds exclusive, worldwide rights to develop and market CAM-3001 under an agreement with CSL Limited.
Ian Anderson, vice president of research – respiratory, inflammation and autoimmunity – at MedImmune, said: “Commencing this trial demonstrates that researchers at MedImmune are at the forefront of innovation using monoclonal antibodies and evaluating their potential to serve as new treatment options for patients with chronic, debilitating inflammatory diseases, including rheumatoid arthritis.”